⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 1, 2024Cancer Management and Research

Human Equilibrative Nucleoside Transporter 1: Novel Biomarker and Prognostic Indicator for Patients with Gemcitabine-Treated Pancreatic Cancer

Jianchun Xiao Fangyu Zhao Wenhao Luo Gang Yang Yi-Cheng Wang Jiangdong Qiu Yueze Liu Lei You Lianfang Zheng Taiping Zhang

View Full Paper

Ask AI

Bookmark

Share

Abstract

This article aimed to find appropriate pancreatic cancer (PC) patients to treat with Gemcitabine with better survival outcomes by detecting hENT1 levels.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Xiao et al. (2024) studied this question.

synapsesocial.com/papers/68e66dccb6db6435875f8f29 https://doi.org/10.2147/cmar.s465098

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1hENT1’s role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patientsOriginal Research · 2023 · 2 citations
2Identification of Putative Equilibrative Nucleoside Transporter Inhibitors Through Dual-Pharmacophore Virtual Screening and Validation in a Gemcitabine-Based Cell AssayOriginal Research · 2026
3Pancreatic cancer with liver metastasis maintaining complete response with gemcitabine monotherapy: A case report2024 · 4 citations
4ST8SIA4-mediated N-glycosylation of hENT1 suppresses gemcitabine resistance in pancreatic cancer2025
5SRS389 - Bypassing hENT1-mediated resistance: irreversible electroporation drives gemcitabine sensitization in pancreatic ductal adenocarcinomaOriginal Research · 2026